{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T06:58:39Z","timestamp":1794553119688,"version":"4.9.1"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,9,15]],"date-time":"2023-09-15T00:00:00Z","timestamp":1694736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,9,15]],"date-time":"2023-09-15T00:00:00Z","timestamp":1694736000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["R01DE028172"],"award-info":[{"award-number":["R01DE028172"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["R01CA226981"],"award-info":[{"award-number":["R01CA226981"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"U.S. Department of Health & Human Services | National Institutes of Health"},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["W81XWH2110433"],"award-info":[{"award-number":["W81XWH2110433"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The poor efficacy of chimeric antigen receptor T-cell therapy (CAR T) for solid tumors is due to insufficient CAR T cell tumor infiltration, in vivo expansion, persistence, and effector function, as well as exhaustion, intrinsic target antigen heterogeneity or antigen loss of target cancer cells, and immunosuppressive tumor microenvironment (TME). Here we describe a broadly applicable nongenetic approach that simultaneously addresses the multiple challenges of CAR T as a therapy for solid tumors. The approach reprograms CAR T cells by exposing them to stressed target cancer cells which have been exposed to the cell stress inducer disulfiram (DSF) and copper (Cu)(DSF\/Cu) plus ionizing irradiation (IR). The reprogrammed CAR T cells acquire early memory-like characteristics, potent cytotoxicity, enhanced in vivo expansion, persistence, and decreased exhaustion. Tumors stressed by DSF\/Cu and IR also reprogram and reverse the immunosuppressive TME in humanized mice. The reprogrammed CAR T cells, derived from peripheral blood mononuclear cells of healthy donors or metastatic female breast cancer patients, induce robust, sustained memory and curative anti-solid tumor responses in multiple xenograft mouse models, establishing proof of concept for empowering CAR T by stressing tumor as a promising\u00a0therapy for solid tumors.<\/jats:p>","DOI":"10.1038\/s41467-023-41282-x","type":"journal-article","created":{"date-parts":[[2023,9,15]],"date-time":"2023-09-15T10:02:37Z","timestamp":1694772157000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":47,"title":["Stressed target cancer cells drive nongenetic reprogramming of CAR T cells and solid tumor microenvironment"],"prefix":"10.1038","volume":"14","author":[{"given":"Yufeng","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David L.","family":"Drum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruochuan","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yida","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengfei","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emre","family":"Dal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingyu","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahrzad","family":"Arya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6387-9361","authenticated-orcid":false,"given":"Song","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6677-1014","authenticated-orcid":false,"given":"Steven J.","family":"Isakoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison M.","family":"Kehlmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2639-8526","authenticated-orcid":false,"given":"Gianpietro","family":"Dotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fubao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina R.","family":"Ferrone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alphonse G.","family":"Taghian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert B.","family":"DeLeo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4201-7009","authenticated-orcid":false,"given":"Marco","family":"Ventin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Cattaneo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4830-9467","authenticated-orcid":false,"given":"Yongxiang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youssef","family":"Jounaidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3184-6493","authenticated-orcid":false,"given":"Peigen","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Maccalli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanyu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0911-8254","authenticated-orcid":false,"given":"Cheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jibing","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7522-6173","authenticated-orcid":false,"given":"Genevieve M.","family":"Boland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruslan I.","family":"Sadreyev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"LaiPing","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2900-8834","authenticated-orcid":false,"given":"Soldano","family":"Ferrone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3674-3685","authenticated-orcid":false,"given":"Xinhui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,9,15]]},"reference":[{"key":"41282_CR1","doi-asserted-by":"publisher","first-page":"95ra73","DOI":"10.1126\/scitranslmed.3002842","volume":"3","author":"M Kalos","year":"2011","unstructured":"Kalos, M. et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci. Transl. Med. 3, 95ra73 (2011).","journal-title":"Sci. Transl. Med."},{"key":"41282_CR2","doi-asserted-by":"publisher","unstructured":"Schaft N. The landscape of CAR-T cell clinical trials against solid tumors-a comprehensive overview. Cancers (Basel). 12, https:\/\/doi.org\/10.3390\/cancers12092567 (2020)","DOI":"10.3390\/cancers12092567"},{"key":"41282_CR3","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1002\/jha2.356","volume":"3","author":"U Patel","year":"2022","unstructured":"Patel, U. et al. CAR T cell therapy in solid tumors: a review of current clinical trials. EJHaem 3, 24\u201331 (2022).","journal-title":"EJHaem"},{"key":"41282_CR4","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1038\/s41591-019-0564-6","volume":"25","author":"RG Majzner","year":"2019","unstructured":"Majzner, R. G. & Mackall, C. L. Clinical lessons learned from the first leg of the CAR T cell journey. Nat. Med. 25, 1341\u20131355 (2019).","journal-title":"Nat. Med."},{"key":"41282_CR5","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1158\/2159-8290.CD-15-0439","volume":"5","author":"M Greaves","year":"2015","unstructured":"Greaves, M. Evolutionary determinants of cancer. Cancer Discov. 5, 806\u2013820 (2015).","journal-title":"Cancer Discov."},{"key":"41282_CR6","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1158\/2159-8290.CD-18-0442","volume":"8","author":"RG Majzner","year":"2018","unstructured":"Majzner, R. G. & Mackall, C. L. Tumor antigen escape from CAR T-cell therapy. Cancer Discov. 8, 1219\u20131226 (2018).","journal-title":"Cancer Discov."},{"key":"41282_CR7","doi-asserted-by":"publisher","unstructured":"O\u2019Rourke, D. M. et al. A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma. Sci. Transl. Med. 9, https:\/\/doi.org\/10.1126\/scitranslmed.aaa0984 (2017).","DOI":"10.1126\/scitranslmed.aaa0984"},{"key":"41282_CR8","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1158\/2326-6066.CIR-16-0376","volume":"5","author":"G Krenciute","year":"2017","unstructured":"Krenciute, G. et al. Transgenic expression of IL15 improves antiglioma activity of IL13R\u03b12-CAR T cells but results in antigen loss variants. Cancer Immunol. Res. 5, 571\u2013581 (2017).","journal-title":"Cancer Immunol. Res."},{"key":"41282_CR9","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1038\/s41587-019-0398-2","volume":"38","author":"X Ma","year":"2020","unstructured":"Ma, X. et al. Interleukin-23 engineering improves CAR T cell function in solid tumors. Nat. Biotechnol. 38, 448\u2013459 (2020).","journal-title":"Nat. Biotechnol."},{"key":"41282_CR10","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1016\/j.ymthe.2018.05.003","volume":"26","author":"CC Kloss","year":"2018","unstructured":"Kloss, C. C. et al. Dominant-negative TGF-\u03b2 receptor enhances PSMA-targeted human CAR T cell proliferation and augments prostate cancer eradication. Mol. Ther. 26, 1855\u20131866 (2018).","journal-title":"Mol. Ther."},{"key":"41282_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-23331-5","volume":"12","author":"L Giuffrida","year":"2021","unstructured":"Giuffrida, L. et al. CRISPR\/Cas9 mediated deletion of the adenosine A2A receptor enhances CAR T cell efficacy. Nat. Commun. 12, 3236 (2021).","journal-title":"Nat. Commun."},{"key":"41282_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-11869-4","volume":"10","author":"L Jin","year":"2019","unstructured":"Jin, L. et al. CXCR1- or CXCR2-modified CAR T cells co-opt IL-8 for maximal antitumor efficacy in solid tumors. Nat. Commun. 10, 4016 (2019).","journal-title":"Nat. Commun."},{"key":"41282_CR13","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/j.ccell.2019.09.006","volume":"36","author":"R Grosser","year":"2019","unstructured":"Grosser, R., Cherkassky, L., Chintala, N. & Adusumilli, P. S. Combination immunotherapy with CAR T cells and checkpoint blockade for the treatment of solid tumors. Cancer Cell. 36, 471\u2013482 (2019).","journal-title":"Cancer Cell."},{"key":"41282_CR14","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1089\/hum.2017.234","volume":"30","author":"B Hu","year":"2019","unstructured":"Hu, B. et al. Nucleofection with plasmid DNA for CRISPR\/Cas9-mediated inactivation of programmed cell death protein 1 in CD133-specific CAR T cells. Hum. Gene Ther. 30, 446\u2013458 (2019).","journal-title":"Hum. Gene Ther."},{"key":"41282_CR15","doi-asserted-by":"publisher","first-page":"4981","DOI":"10.1016\/j.cell.2021.08.004","volume":"184","author":"LR Johnson","year":"2021","unstructured":"Johnson, L. R. et al. The immunostimulatory RNA RN7SL1 enables CAR-T cells to enhance autonomous and endogenous immune function. Cell 184, 4981\u20134995.e14 (2021).","journal-title":"Cell"},{"key":"41282_CR16","doi-asserted-by":"publisher","first-page":"6050","DOI":"10.1182\/blood-2011-05-354449","volume":"118","author":"CU Louis","year":"2011","unstructured":"Louis, C. U. et al. Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma. Blood 118, 6050\u20136056 (2011).","journal-title":"Blood"},{"key":"41282_CR17","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1038\/s43018-021-00207-7","volume":"2","author":"L Biasco","year":"2021","unstructured":"Biasco, L. et al. Clonal expansion of T memory stem cells determines early anti-leukemic responses and long-term CAR T cell persistence in patients. Nat. Cancer 2, 629\u2013642 (2021).","journal-title":"Nat. Cancer"},{"key":"41282_CR18","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/s41591-018-0010-1","volume":"24","author":"JA Fraietta","year":"2018","unstructured":"Fraietta, J. A. et al. Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia. Nat. Med. 24, 563\u2013571 (2018).","journal-title":"Nat. Med."},{"key":"41282_CR19","doi-asserted-by":"publisher","unstructured":"Westin, J. R. et al. Survival with axicabtagene ciloleucel in large B-Cell lymphoma. N Engl J Med. Published online June 5, 2023. https:\/\/doi.org\/10.1056\/NEJMoa2301665.","DOI":"10.1056\/NEJMoa2301665"},{"key":"41282_CR20","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1111\/j.1600-0447.1992.tb03310.x","volume":"369","author":"B Johansson","year":"1992","unstructured":"Johansson, B. A review of the pharmacokinetics and pharmacodynamics of disulfiram and its metabolites. Acta Psychiatr. Scand. Suppl. 369, 15\u201326 (1992).","journal-title":"Acta Psychiatr. Scand. Suppl."},{"key":"41282_CR21","doi-asserted-by":"publisher","first-page":"13334","DOI":"10.1039\/C4CC04767B","volume":"50","author":"DJ Lewis","year":"2014","unstructured":"Lewis, D. J., Deshmukh, P., Tedstone, A. A., Tuna, F. & O\u2019Brien, P. On the interaction of copper(II) with disulfiram. Chem. Commun. (Camb.). 50, 13334\u201313337 (2014).","journal-title":"Chem. Commun. (Camb.)."},{"key":"41282_CR22","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1038\/nature25016","volume":"552","author":"Z Skrott","year":"2017","unstructured":"Skrott, Z. et al. Alcohol-abuse drug disulfiram targets cancer via p97 segregase adaptor NPL4. Nature 552, 194\u2013199 (2017).","journal-title":"Nature"},{"key":"41282_CR23","first-page":"1266","volume":"9","author":"X Zhang","year":"2019","unstructured":"Zhang, X. et al. Induction of autophagy-dependent apoptosis in cancer cells through activation of ER stress: an uncovered anti-cancer mechanism by anti-alcoholism drug disulfiram. Am. J. Cancer Res. 9, 1266\u20131281 (2019).","journal-title":"Am. J. Cancer Res."},{"key":"41282_CR24","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-019-0507-3","volume":"18","author":"T Sun","year":"2020","unstructured":"Sun, T. et al. Induction of immunogenic cell death in radiation-resistant breast cancer stem cells by repurposing anti-alcoholism drug disulfiram. Cell Commun. Signal. 18, 36 (2020).","journal-title":"Cell Commun. Signal."},{"key":"41282_CR25","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1126\/science.aav8692","volume":"365","author":"L Ma","year":"2019","unstructured":"Ma, L. et al. Enhanced CAR-T cell activity against solid tumors by vaccine boosting through the chimeric receptor. Science 365, 162\u2013168 (2019).","journal-title":"Science"},{"key":"41282_CR26","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/sj.cdd.4402269","volume":"15","author":"A Tesniere","year":"2008","unstructured":"Tesniere, A. et al. Molecular characteristics of immunogenic cancer cell death. Cell Death Differ. 15, 3\u201312 (2008).","journal-title":"Cell Death Differ."},{"key":"41282_CR27","doi-asserted-by":"publisher","first-page":"58754","DOI":"10.18632\/oncotarget.17678","volume":"8","author":"Q Xu","year":"2017","unstructured":"Xu, Q., Chen, C., Lin, A. & Xie, Y. Endoplasmic reticulum stress-mediated membrane expression of CRT\/ERp57 induces immunogenic apoptosis in drug-resistant endometrial cancer cells. Oncotarget 8, 58754\u201358764 (2017).","journal-title":"Oncotarget"},{"key":"41282_CR28","doi-asserted-by":"publisher","first-page":"9974","DOI":"10.18632\/oncotarget.14285","volume":"8","author":"F Dufour","year":"2017","unstructured":"Dufour, F. et al. TRAIL receptor gene editing unveils TRAIL-R1 as a master player of apoptosis induced by TRAIL and ER stress. Oncotarget 8, 9974\u20139985 (2017).","journal-title":"Oncotarget"},{"key":"41282_CR29","doi-asserted-by":"publisher","first-page":"3037","DOI":"10.1038\/s41418-020-0559-3","volume":"27","author":"D St\u00f6hr","year":"2020","unstructured":"St\u00f6hr, D. et al. Stress-induced TRAILR2 expression overcomes TRAIL resistance in cancer cell spheroids. Cell Death Differ. 27, 3037\u20133052 (2020).","journal-title":"Cell Death Differ."},{"key":"41282_CR30","doi-asserted-by":"publisher","first-page":"7410","DOI":"10.1158\/0008-5472.CAN-10-1134","volume":"71","author":"X Wang","year":"2011","unstructured":"Wang, X. et al. Functional characterization of an scFv-Fc antibody that immunotherapeutically targets the common cancer cell surface proteoglycan CSPG4. Cancer Res. 71, 7410\u20137422 (2011).","journal-title":"Cancer Res."},{"key":"41282_CR31","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1158\/1078-0432.CCR-20-2584","volume":"27","author":"F Kontos","year":"2021","unstructured":"Kontos, F. et al. B7-H3: an attractive target for antibody-based immunotherapy. Clin. Cancer Res. 27, 1227\u20131235 (2021).","journal-title":"Clin. Cancer Res."},{"key":"41282_CR32","doi-asserted-by":"publisher","first-page":"2542","DOI":"10.1016\/j.ymthe.2018.09.008","volume":"26","author":"C DeSelm","year":"2018","unstructured":"DeSelm, C. et al. Low-dose radiation conditioning enables CAR T cells to mitigate antigen escape. Mol. Ther. 26, 2542\u20132552 (2018).","journal-title":"Mol. Ther."},{"key":"41282_CR33","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/s41416-018-0328-y","volume":"120","author":"P Berraondo","year":"2019","unstructured":"Berraondo, P. et al. Cytokines in clinical cancer immunotherapy. Br. J. Cancer 120, 6\u201315 (2019).","journal-title":"Br. J. Cancer"},{"key":"41282_CR34","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1002\/emmm.201101140","volume":"4","author":"KP Lai","year":"2012","unstructured":"Lai, K. P., Yamashita, S., Huang, C. K., Yeh, S. & Chang, C. Loss of stromal androgen receptor leads to suppressed prostate tumourigenesis via modulation of pro-inflammatory cytokines\/chemokines. EMBO Mol. Med. 4, 791\u2013807 (2012).","journal-title":"EMBO Mol. Med."},{"key":"41282_CR35","doi-asserted-by":"publisher","first-page":"287","DOI":"10.3389\/fonc.2018.00287","volume":"8","author":"E Bousoik","year":"2018","unstructured":"Bousoik, E. & Montazeri Aliabadi, H. \u201cDo We Know Jack\u201d About JAK? A closer look at JAK\/STAT signaling pathway. Front. Oncol. 8, 287 (2018).","journal-title":"Front. Oncol."},{"key":"41282_CR36","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1038\/nm.4478","volume":"24","author":"Y Kagoya","year":"2018","unstructured":"Kagoya, Y. et al. A novel chimeric antigen receptor containing a JAK-STAT signaling domain mediates superior antitumor effects. Nat. Med. 24, 352\u2013359 (2018).","journal-title":"Nat. Med."},{"key":"41282_CR37","doi-asserted-by":"publisher","first-page":"e110636","DOI":"10.15252\/embj.2022110636","volume":"41","author":"Q Wang","year":"2022","unstructured":"Wang, Q. et al. Disulfiram bolsters T-cell anti-tumor immunity through direct activation of LCK-mediated TCR signaling. EMBO J. 41, e110636 (2022).","journal-title":"EMBO J."},{"key":"41282_CR38","doi-asserted-by":"publisher","first-page":"2994","DOI":"10.1002\/1878-0261.12851","volume":"14","author":"A Ahmed","year":"2020","unstructured":"Ahmed, A. & Tait, S. W. G. Targeting immunogenic cell death in cancer. Mol. Oncol. 14, 2994\u20133006 (2020).","journal-title":"Mol. Oncol."},{"key":"41282_CR39","doi-asserted-by":"publisher","first-page":"1193963","DOI":"10.3389\/fonc.2023.1193963","volume":"13","author":"M Ventin","year":"2023","unstructured":"Ventin, M. et al. B7-H3-targeted CAR T cell activity is enhanced by radiotherapy in solid cancers. Front. Oncol. 13, 1193963 (2023).","journal-title":"Front. Oncol."},{"key":"41282_CR40","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1158\/1535-7163.MCT-20-0446","volume":"20","author":"Y Zhang","year":"2021","unstructured":"Zhang, Y. et al. Targeting radiation-resistant prostate cancer stem cells by B7-H3 CAR T cells. Mol. Cancer Ther. 20, 577\u2013588 (2021).","journal-title":"Mol. Cancer Ther."},{"key":"41282_CR41","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-022-02778-6","volume":"22","author":"M Al-Haideri","year":"2022","unstructured":"Al-Haideri, M. et al. CAR-T cell combination therapy: the next revolution in cancer treatment. Cancer Cell Int. 22, 365 (2022).","journal-title":"Cancer Cell Int."},{"key":"41282_CR42","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1001\/jamaoncol.2019.0192","volume":"5","author":"QN Nguyen","year":"2019","unstructured":"Nguyen, Q. N. et al. Single-fraction stereotactic vs conventional multifraction radiotherapy for pain relief in patients with predominantly nonspine bone metastases: a randomized phase 2 trial. JAMA Oncol. 5, 872\u2013878 (2019).","journal-title":"JAMA Oncol."},{"key":"41282_CR43","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1001\/jamaoncol.2021.0039","volume":"7","author":"C Greco","year":"2021","unstructured":"Greco, C. et al. Safety and efficacy of virtual prostatectomy with single-dose radiotherapy in patients with intermediate-risk prostate cancer: results from the PROSINT Phase 2 Randomized Clinical Trial. JAMA Oncol. 7, 700\u2013708 (2021).","journal-title":"JAMA Oncol."},{"key":"41282_CR44","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1016\/j.celrep.2014.08.029","volume":"8","author":"DT Ting","year":"2014","unstructured":"Ting, D. T. et al. Single-cell RNA sequencing identifies extracellular matrix gene expression by pancreatic circulating tumor cells. Cell Rep. 8, 1905\u20131918 (2014).","journal-title":"Cell Rep."},{"key":"41282_CR45","doi-asserted-by":"publisher","first-page":"7064","DOI":"10.1074\/jbc.M708530200","volume":"283","author":"D Zhou","year":"2008","unstructured":"Zhou, D. et al. Phosphorylation of eIF2 directs ATF5 translational control in response to diverse stress conditions. J. Biol. Chem. 283, 7064\u20137073 (2008).","journal-title":"J. Biol. Chem."},{"key":"41282_CR46","doi-asserted-by":"publisher","first-page":"3896","DOI":"10.1016\/j.cell.2022.08.025","volume":"185","author":"HJ Shayya","year":"2022","unstructured":"Shayya, H. J. et al. ER stress transforms random olfactory receptor choice into axon targeting precision. Cell 185, 3896\u20133912.e22 (2022).","journal-title":"Cell"},{"key":"41282_CR47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.exer.2017.01.002","volume":"155","author":"S Zhu","year":"2017","unstructured":"Zhu, S. et al. PERK and XBP1 differentially regulate CXCL10 and CCL2 production. Exp. Eye Res. 155, 1\u201314 (2017).","journal-title":"Exp. Eye Res."},{"key":"41282_CR48","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1016\/j.devcel.2020.01.031","volume":"52","author":"GP Sullivan","year":"2020","unstructured":"Sullivan, G. P. et al. TRAIL receptors serve as stress-associated molecular patterns to promote ER-stress-induced inflammation. Dev. Cell. 52, 714\u2013730.e5 (2020).","journal-title":"Dev. Cell."},{"key":"41282_CR49","doi-asserted-by":"publisher","first-page":"111255","DOI":"10.1016\/j.celrep.2022.111255","volume":"40","author":"B Yang","year":"2022","unstructured":"Yang, B. et al. Macrophages and neutrophils are necessary for ER stress-induced \u03b2 cell loss. Cell Rep. 40, 111255 (2022).","journal-title":"Cell Rep."},{"key":"41282_CR50","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-06811-z","volume":"9","author":"Y Li","year":"2018","unstructured":"Li, Y. et al. Heterozygous deletion of chromosome 17p renders prostate cancer vulnerable to inhibition of RNA polymerase II. Nat. Commun. 9, 4394 (2018).","journal-title":"Nat. Commun."},{"key":"41282_CR51","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1016\/j.cell.2016.11.022","volume":"167","author":"JL Benci","year":"2016","unstructured":"Benci, J. L. et al. Tumor interferon signaling regulates a multigenic resistance program to immune checkpoint blockade. Cell 167, 1540\u20131554.e12 (2016).","journal-title":"Cell"},{"key":"41282_CR52","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1016\/j.gpb.2021.08.001","volume":"19","author":"T Chen","year":"2021","unstructured":"Chen, T. et al. The genome sequence archive family: toward explosive data growth and diverse data types. Genomics Proteom. Bioinforma. 19, 578\u2013583 (2021).","journal-title":"Genomics Proteom. Bioinforma."},{"key":"41282_CR53","doi-asserted-by":"publisher","first-page":"D27","DOI":"10.1093\/nar\/gkab951","volume":"50","author":"CNCB-NGDC Members and Partners.","year":"2022","unstructured":"CNCB-NGDC Members and Partners. Database resources of the National Genomics Data Center, China National Center for Bioinformation in 2022. Nucleic Acids Res. 50, D27\u2013D38 (2022).","journal-title":"Nucleic Acids Res."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-023-41282-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-023-41282-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-023-41282-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,17]],"date-time":"2023-11-17T17:08:08Z","timestamp":1700240888000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-023-41282-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,15]]},"references-count":53,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["41282"],"URL":"https:\/\/doi.org\/10.1038\/s41467-023-41282-x","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,15]]},"assertion":[{"value":"31 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 August 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"G.D., S.F., X.W., and C.R.F. report two patents on the B7-H3 CAR T cells (US10519214B2: Methods and compositions for chimeric antigen receptor targeting cancer cells) and CSPG4 CAR T cells (US20210252067A1: Methods and compositions for chimeric antigen receptor targeting cancer cells). The remaining authors declare no other competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"5727"}}